FY2024 EPS Estimates for Pyxis Oncology Lowered by Analyst

Pyxis Oncology, Inc. (NASDAQ:PYXS) – William Blair lowered their FY2024 EPS estimates for Pyxis Oncology in a report issued on Tuesday, November 12th. William Blair analyst A. Hsieh now expects that the company will post earnings per share of ($1.02) for the year, down from their prior estimate of ($1.00). The consensus estimate for Pyxis Oncology’s current full-year earnings is ($1.04) per share. William Blair also issued estimates for Pyxis Oncology’s Q4 2024 earnings at ($0.30) EPS, Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.31) EPS, FY2025 earnings at ($1.26) EPS and FY2026 earnings at ($1.32) EPS.

A number of other analysts also recently weighed in on PYXS. Stifel Nicolaus started coverage on Pyxis Oncology in a research report on Thursday, August 8th. They set a “buy” rating and a $10.00 target price for the company. Royal Bank of Canada reiterated an “outperform” rating and set a $7.00 price objective on shares of Pyxis Oncology in a research note on Thursday, September 19th. HC Wainwright reissued a “buy” rating and issued a $7.00 target price on shares of Pyxis Oncology in a report on Friday, August 16th. Finally, Stephens initiated coverage on shares of Pyxis Oncology in a report on Friday, November 8th. They set an “overweight” rating and a $13.00 price target for the company. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $9.57.

Pyxis Oncology Price Performance

Shares of NASDAQ:PYXS opened at $4.19 on Friday. The business’s 50 day simple moving average is $3.68 and its 200 day simple moving average is $3.66. Pyxis Oncology has a 1 year low of $1.35 and a 1 year high of $6.85. The company has a market capitalization of $249.16 million, a P/E ratio of -4.07 and a beta of 1.27.

Pyxis Oncology (NASDAQ:PYXS) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.04.

Hedge Funds Weigh In On Pyxis Oncology

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Fullcircle Wealth LLC bought a new stake in shares of Pyxis Oncology during the second quarter worth about $40,000. SG Americas Securities LLC bought a new stake in Pyxis Oncology during the 1st quarter worth approximately $59,000. Intech Investment Management LLC bought a new stake in Pyxis Oncology during the 3rd quarter worth approximately $55,000. MetLife Investment Management LLC increased its position in Pyxis Oncology by 41.1% in the 3rd quarter. MetLife Investment Management LLC now owns 18,818 shares of the company’s stock valued at $69,000 after acquiring an additional 5,484 shares during the period. Finally, The Manufacturers Life Insurance Company bought a new position in shares of Pyxis Oncology during the second quarter valued at $65,000. Institutional investors own 39.09% of the company’s stock.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.